Leandro Jonata Oliveira, Medical Oncologist at Einstein Hospital Israelita, posted on X:
“Oncotype DX in eBC: Brazilian RWE
Key findings:
Potential 12.6% reduction in CT indication
Largest impact:
- Post N1: 94% reduction
- N0 ≥50y and high clin risk: 65% reduction
Predictors of RS>25:
- Ki67>20%, PR≤30%, G3
RS < 25: excellent 5y DFS.”
Title: Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)
Authors: Leandro Oliveira, Daniella Araújo, Júlio Araújo, Daniela Rosa, Artur Katz, Daniele Assad-Suzuki, Daniel Argolo, Solange Sanches, Laura Testa, José Bines, Rafael Kaliks, Debora Gagliato, Romualdo Barroso-Sousa, Tatiana Corrêa, Andrea Shimada, Carlos Anjos, Rudinei Linck, Thais Megid, Daniel Batista, Daniel Gomes, Marcelle Cesca, Débora Gaudêncio, Larissa Moura, Renata Bonadio, Zenaide Souza, Juliana Beal, Mario Lopes, Leticia Sales, Júlia Marlière, Max Mano
Read the Full Article.
ctDNA in Early Breast Cancer: Treating the Blood Before the Tumor?
